Ocuphire Pharma Inc (OCUP)

$1.60 0.07 (4.23%)

13:12 EDT OCUP Stock Quote Delayed 30 Minutes

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023

By InvestorPlace Earnings Mar 15, 2024

OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

3 Value Stocks to Buy on the Dip: February 2024

Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 51,434

Day's Range $1.55 - $1.61

52-Week Range $1.50 - $6.60

Dividend & Yield N/A (N/A)

OCUP Stock Predictions, Articles, and Ocuphire Pharma Inc News

From InvestorPlace
From the Web

Surprise! These 3 Penny Stocks Pack Powerful Financials.

By Josh Enomoto, InvestorPlace Contributor Jul 10, 2023

While investing in penny stocks carries a rough reputation (to put it nicely), these speculative entities just might surprise you.

The 7 Best Stocks Under $10 to Buy in May

By Josh Enomoto, InvestorPlace Contributor May 3, 2023

While quality matters in the market, these best stocks under $10 to buy gives you some potential diamonds in the rough.

7 Small-Cap Biotech Stocks with Massive Potential

By Josh Enomoto, InvestorPlace Contributor Apr 27, 2023

Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

By Josh Enomoto, InvestorPlace Contributor Apr 5, 2023

Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own.

Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?

By William White, InvestorPlace Writer Jan 26, 2023

Ocuphire Pharma (OCUP) stock is falling on Thursday after the company posted mixed results from a Phase 2 clinical trial.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jan 26, 2023

We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Nov 8, 2022

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Oct 26, 2022

It's time to start off the day with a breakdown of the biggest pre-market stock movers for Wednesday morning and the latest news!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Nov 24, 2021

We're starting the last day of this short holiday week with a dive into the biggest pre-market stock movers for Wednesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jul 1, 2021

Good morning, investor! We're starting the day off with a deep dive into the biggest pre-market stock movers for Thursday!

Ocuphire Pharma appointed Nirav Jhaveri as CFO (NASDAQ:OCUP)

From Seeking Alpha Feb 14, 2024

Ocuphire Pharma strengthens leadership team with the appointment of Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific and Development Officer.

Ocuphire Pharma files for a $175M mixed securities shelf (NASDAQ:OCUP)

From Seeking Alpha Jan 10, 2024

Ocuphire Pharma (OCUP) files prospectus for a mixed shelf offering, aiming to raise up to $175M; not an offer to sell securities.

Ocuphire announces appointment of Joseph Schachle as chief operating officer (NASDAQ:OCUP)

From Seeking Alpha Nov 27, 2023

Ocuphire Pharma appoints Joseph Schachle as chief operating officer, signaling strategic expansion for the advancement of their lead retina asset.

Ocuphire Pharma appoints George Magrath as CEO (NASDAQ:OCUP)

From Seeking Alpha Nov 1, 2023

Ocuphire Pharma announces George Magrath as new CEO, replacing interim chief Rick Rodgers.

OCUP stock rises as eye therapy goes under FDA review (NASDAQ:OCUP)

From Seeking Alpha Feb 13, 2023

Ocuphire Pharma (OCUP) gained ~9% pre-market Monday after announcing that the FDA accepted its marketing application for experimental eye drop Nyxol. Read the full story here.

Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP) and Irhythm Technologies (IRTC)

From TipRanks Dec 6, 2022

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocuphire Pharma (OCUP – Research Report) and Irhythm...

ADVERTISEMENT